Closed · RFA-AI-22-075 · CFDA 93.855 · Discretionary

Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $1M
Award range
Closed
Status
February 22, 2023
Close date
-
Expected awards

The verdict

Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $1,000,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $1M
award range
Closed
application status
93.855
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Limited Competition: Resources and Workforce… is closed (last close February 22, 2023). The parent program page for CFDA 93.855 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed February 22, 2023

Posted Dec 14 Closes Feb 22

Instrument

Cooperative Agreement

Description

The goal of this Funding Opportunity Announcement (FOA) is to provide support to the 12 Regional Biocontainment Laboratories (RBLs) previously constructed with NIAID support to enable them to develop and maintain resources, staff, and facilities necessary to address biodefense agents, emerging infectious diseases, and pandemic preparedness in line with NIAID priorities. Operations support is provided for facility maintenance and operations, as well as Biosafety Level 3 (BSL-3) practices support for personnel working in and around BSL-3 space and associated building systems. An optional component would allow the RBLs to provide specialized services essential to support BSL3 activities. The RBLs will serve as regional resources for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAIDs biodefense, emerging infectious diseases, and pandemic preparedness research efforts.

Small-business / for-profit corridor · RFA-AI-22-075

Limited Competition: Resources and Workforce… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Parent Grant Program

CFDA 93.855

Allergy, Immunology, and Transplantation Research

National Institutes of Health

View program →

Agency Contact

NIH Grants Information grantsinfo@nih.gov

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

Limited Competition: Resources and Workforce… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.855 may publish future NOFOs under the same assistance listing. Open program
  • Allergy, Immunology, and Transplantation Rese… indexes 67 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants